APIM THERAPEUTICS ANNOUNCES THAT THE FIRST PATIENT HAS BEEN TREATED WITH ATX-101 IN A PHASE I/II OVARIAN CANCER STUDY
Trondheim, 25 November 2021 APIM Therapeutics (APIM), a clinical stage biotech company, focusing on the development of novel peptide therapeutics targeting PCNA (Proliferating Cell Nuclear Antigen), announced today that the first patient has been treated in a clinical Phase 1b/2a study in ovarian cancer. The clinical study (ClinicalTrials.gov Identifier: NCT04814875) investigates ATX-101, the lead compound of APIM’s development program, in combination with platinum-based chemotherapy in patients suffering from recurrent, platinum sensitive ovarian, fallopian tube and primary